Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1811 +/- Pyrotinib in HER2+ Breast Cancer
NCT05635487Phase 2Recruiting
- Sponsor
- Shengjing Hospital of China Medical University
- Start
- Mar 2023
- Primary completion
- Feb 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab rezetecan in breast cancer, sponsored by Shengjing Hospital of China Medical University. Started Mar 2023; status: recruiting.
02
Drugs
trastuzumab rezetecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05635487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05635487.